Gene Inhibition Therapy

shRNA Versus Artificial miRNA

A summary of the key differences between shRNA and artificial microRNA.

Let’s now summarize the key differences between shRNA and artificial microRNA.

The use of shRNA results in specific gene knockdown and high levels of shRNA expression. This strategy has been used widely because of the simple design, long-term expression, and stability of shRNA. The high levels of shRNAs can potentially oversaturate the endogenous RNAi pathway and result in possible non-specific toxicity. However, structural modifications have been made to address these issues18,47-50.

In contrast, artificial microRNAs result in less specific gene knockdown and typically lower level of expression. These properties make artificial microRNAs less likely to disrupt endogenous RNAi pathways than shRNAs, which lowers the risk of non-specific toxicity18,47,51.

Because of their simple design and long-term expression and stability, shRNAs have been investigated in a wide variety of applications, including myocardial ischemia, HIV, and tumor growth18,52,53.

Artificial microRNAs have also been investigated in a variety of diseases such as hepatitis B54,55, amyotrophic lateral sclerosis56, facioscapulohumeral muscular dystrophy57, and Huntington’s disease58.

Because all cases of Huntington’s disease are caused by the same basic mutation that results in the accumulation of a mutant protein, it is an ideal target for gene inhibition therapies59. In Huntington’s disease, mutations in the huntingtin or HTT gene lead to a toxic accumulation of the mutant HTT protein in the brain, which causes massive neurodegeneration and clinical symptoms associated with the disease60. By selectively reducing mutant HTT expression, gene inhibition strategies could reverse the pathological features of Huntington’s disease associated with aberrant accumulation of HTT protein60.

This concludes the module on how gene inhibition therapy works. Please return to the Education Center to learn more about gene inhibition and other gene therapy mechanisms.


  • Wang D, Gao G. Discov Med 2014;18(98):151–161.
  • Strachan T, Read AP. Genetic approaches to treating disease: In: Human Molecular Genetics. 5th ed. Florida: CRC Press, 2018:696–699.
  • NCBI. Gene silencing. Available at: Accessed January 30, 2020.
  • Grimm D, Kay MA. Hematology Am Soc Educ Program 2007;2007:473–481.
  • Koerner MV, et al. Genes Dev 2018;32(23–24):1514–1524.
  • Haussecker D, Kay MA. Science 2015;347(6226):1069–1107.
  • Karaki S, et al. Antisense oligonucleotides, a novel developing targeting therapy. In: Antisense Therapy. Available at: Accessed February 28, 2020.
  • Mendonça LS, et al. J Drug Del Sci Tech 2012;22(1):65–73.
  • Sliva K, Schnierle BS. Virol J 2010;7:248.
  • Wang J, et al. AAPS J 2010;12(4):492–503.
  • U.S. FDA. Approved Cellular and Gene Therapy Products. Available at: Accessed March 27, 2020.
  • Wang D, et al. Nat Rev Drug Discov 2019;18(5):358–378.
  • Sibley C, et al. Mol Ther 2010;18(3):466–476.
  • Wang D, et al. Cell 2020;181(1):136–150.
  • Granados-Riveron JT, Aquino-Jarquin G. Cancer Res 2018;78(15):4107–4113.
  • Chery J. Postdoc J 2016;4(7):35–50.
  • Ozcan G, et al. Adv Drug Deliv Rev 2015;87:108–119.
  • Borel F, et al. Mol Ther 2014;22(4):692–701.
  • Fire A, et al. Nature 1998;391:806–811.
  • The Nobel Prize. Advanced information: RNA interference. Available at: Accessed March 31, 2020.
  • Lam JK, et al. Mol Ther Nucleic Acids 2015;4:e252.
  • Pushparaj PN, et al. J Dent Res 2008;87(11):992–1003.
  • Catalonotto C, et al. Int J Mol Sci 2016;17(10):1712.
  • Novák J, et al. Theranostics 2014;4(2):119–133.
  • Zampetaki A, et al. Circ Res 2010;107(6):810–817.
  • Hydbring P, Badalian-Very G. F1000Res 2013;2:136.
  • Chery J. Postdoc J 2016;4(7):35–50.
  • Fellmann C, Lowe SW. Nat Cell Biol 2014;16(1):10–18.
  • Ramachandran PV, Ignacimuthu S. Appl Biochem Biotechnol 2013;169:1774–1789.
  • Herrera-Carrillo E, et al. Hum Gene Ther Methods 2017;28(4):117–190.
  • Park JH, Shin C. BMB Rep 2014;47(8):417–423.
  • Stein P, et al. PLoS Genet 2015;11(2):e1005013.
  • Piatek MJ, Werner A. Biochem Soc Trans 2014;42(4):1174–1179.
  • Laganà A, et al. Front Bioeng Biotechnol 2014;2:65.
  • Chakraborty C, et al. Mol Ther Nucleic Acids 2017;8:132–143.
  • Alnylam Pharmaceuticals. Press release. August 10, 2018. Available at: Accessed March 31, 2020.
  • Onpattro® [package insert]. 2018. Available at: Accessed March 31, 2020.
  • Moore CB, et al. Methods Mol Biol 2010;629:141–158.
  • Bofill-De Ros X, Gu S. Methods 2016;103:157–166.
  • Myburgh R, et al. Mol Ther Nucl Acids 2014;3:e207.
  • Chen X, et al. Cancer Metastasis Rev 2018;37(1):107–124.
  • Kurreck J. J RNAi Gene Silencing 2017;13:545–547.
  • Rao DD, et al. Adv Drug Del Rev 2009;61:746–759.
  • Boudreau RL, et al. Mol Ther 2009;17(1):169–175.
  • Fan J, et al. Cancer Gene Ther 2019. doi: 10.1038/s41417-019-0113-y [Epub ahead of print].
  • Merlin S, Follenzi AT. Mol Ther Meth Clin Dev 2019;12:223–232.
  • Fowler DK, et al. Nucleic Acids Res 2016;44(5):e48.
  • Grimm D, et al. Nature 2006;441:537–541.
  • Ehlert EM, et al. BMC Neurosci 2010;11:20.
  • Giering JC, et al. Mol Ther 2008;16:1630–1636.
  • Wu H, et al. PLoS One 2011;6:e28580.
  • News Medical Life Sciences. Short Hairpin RNA (shRNA) Interference: Therapeutic Applications. Available at: Accessed March 31, 2020.
  • Wolstein O, et al. Mol Ther Methods Clin Dev 2014;1:11.
  • Ahn M, et al. Hum Gene Ther 2011;22(12):1483–1497.
  • Ma J, et al. PLoS One 2012;7(10):e46096.
  • Stoica L, et al. Ann Neurol 2016;79(4):687–700.
  • Wallace LM, et al. Mol Ther 2012;20(7):1417–1423.
  • Spronck EA, et al. Mol Ther Methods Clin Dev 2019;13:334–343.
  • Wild EJ, Tabrizi S. Lancet Neurol 2017;16(10):837–847.
  • Vagner R, et al. Neurol Res Int 2012;2012:358370.